At a glance
ClinicalIndex Comparison RecordN/ACompleted· 92 enrolled
Drug / intervention
Nervio-Xdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Controlled, Double-Blind Trial on the Efficacy and Safety of Amygdala Temporal Interference Stimulation for the Treatment of Depression.
In Brief
A clinical study evaluating Nervio-X for Major Depressive Disorder. Completed, enrolled 92 participants across 3 sites.
Detailed Summary
The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes. The intervention's safety and efficacy will be evaluated using an assessment incorporating depressive symptomatology, cognitive abilities, and daily functions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesChina
CollaboratorsTianjin Anding Hospital, Shanghai East Hospital
Timeline
N/ACompletedFinished
20252026
First PostedJun 2024
Enrollment StartJul 2024
Primary CompletionMay 2025
TodayJul 2026
First PostedJun 27, 2024
Enrollment StartJul 24, 2024
Primary CompletionMay 1, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.0 years ago
Interventions
Nervio-Xdevice
An 8-channel TIS device developed by NEURODOME Corporation.